See more : China Financial Services Holdings Limited (0605.HK) Income Statement Analysis – Financial Results
Complete financial analysis of NovaBay Pharmaceuticals, Inc. (NBY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NovaBay Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Bambino Agro Industries Limited (BAMBINO.BO) Income Statement Analysis – Financial Results
- C. E. Info Systems Limited (MAPMYINDIA.BO) Income Statement Analysis – Financial Results
- Lithium Americas (Argentina) Corp. (LAAC) Income Statement Analysis – Financial Results
- Targa Resources Corp. (0LD9.L) Income Statement Analysis – Financial Results
- Viavi Solutions Inc. (VIAV) Income Statement Analysis – Financial Results
NovaBay Pharmaceuticals, Inc. (NBY)
About NovaBay Pharmaceuticals, Inc.
NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. It offers Avenova, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, SPF, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through retailers, digital beauty channels, and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 14.73M | 14.40M | 8.42M | 9.93M | 6.60M | 12.51M | 18.23M | 11.90M | 4.38M | 1.05M | 3.48M | 6.95M | 11.02M | 9.75M | 15.68M | 6.72M | 5.91M | 1.53M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 6.83M | 6.62M | 2.78M | 3.97M | 1.74M | 1.50M | 2.78M | 2.46M | 1.26M | 486.00K | 162.00K | 8.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 7.90M | 7.78M | 5.65M | 5.96M | 4.86M | 11.01M | 15.45M | 9.43M | 3.12M | 568.00K | 3.32M | 6.94M | 11.02M | 9.75M | 15.68M | 6.72M | 5.91M | 1.53M | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 53.61% | 54.02% | 67.03% | 60.04% | 73.66% | 87.98% | 84.73% | 79.29% | 71.22% | 53.89% | 95.34% | 99.88% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 68.00K | 174.00K | 44.00K | 285.00K | 184.00K | 259.00K | 410.00K | 1.37M | 6.05M | 9.51M | 12.46M | 9.28M | 9.91M | 8.62M | 7.34M | 9.60M | 7.42M | 4.09M | 1.95M | 0.00 | 270.00K |
| General & Administrative | 6.33M | 7.49M | 7.24M | 5.93M | 5.31M | 5.83M | 8.64M | 7.24M | 18.09M | 7.94M | 6.34M | 5.98M | 5.43M | 5.65M | 5.61M | 5.64M | 4.37M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 6.50M | 7.80M | 7.22M | 6.17M | 8.77M | 12.79M | 13.71M | 11.81M | 10.52M | 1.75M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 12.83M | 15.29M | 14.46M | 12.11M | 14.08M | 18.62M | 22.35M | 19.04M | 18.09M | 7.94M | 6.34M | 5.98M | 5.43M | 5.65M | 5.61M | 5.64M | 4.37M | 2.97M | 1.62M | 0.00 | 0.00 |
| Other Expenses | 0.00 | -276.00K | -1.58M | 605.00K | -1.43M | 19.00K | 12.00K | -68.00K | -96.00K | 22.00K | 1.00K | -155.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -2.80M | 0.00 |
| Operating Expenses | 12.90M | 15.46M | 14.51M | 12.39M | 14.26M | 18.88M | 22.76M | 20.42M | 24.13M | 17.45M | 18.80M | 15.26M | 15.34M | 14.27M | 12.94M | 15.23M | 11.79M | 7.06M | 3.57M | -2.80M | 953.00K |
| Cost & Expenses | 19.73M | 22.08M | 17.28M | 16.36M | 16.00M | 20.38M | 25.54M | 22.88M | 25.40M | 17.93M | 18.96M | 15.26M | 15.34M | 14.27M | 12.94M | 15.23M | 11.79M | 7.06M | 3.57M | -2.80M | 953.00K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 1.05M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 203.00K | 483.00K | 119.00K | 51.00K | 65.00K | 266.00K | 95.00K | 114.00K | 164.00K | 232.00K | 314.00K | 341.00K | 425.00K | 427.00K | 373.00K | 304.00K | 183.00K | 74.00K | 48.00K | 0.00 | 24.00K |
| EBITDA | -4.80M | -7.20M | -8.74M | -6.38M | -9.34M | -7.61M | -7.22M | -10.87M | -20.97M | -16.67M | -15.17M | -7.97M | -3.90M | -4.09M | 3.15M | -7.81M | -5.21M | -5.45M | -3.42M | -2.80M | -929.00K |
| EBITDA Ratio | -32.60% | -31.55% | -158.63% | -11.70% | -159.24% | -71.28% | -39.03% | -73.71% | -524.97% | -1,737.19% | -420.39% | -135.41% | -28.44% | -44.57% | 20.08% | -127.97% | -104.53% | -371.30% | 0.00% | 0.00% | 0.00% |
| Operating Income | -5.00M | -7.68M | -8.86M | -6.43M | -9.40M | -7.87M | -7.31M | -10.98M | -21.01M | -16.88M | -15.49M | -8.31M | -4.32M | -4.52M | 2.74M | -8.51M | -5.88M | -5.53M | -3.57M | -2.80M | -953.00K |
| Operating Income Ratio | -33.97% | -53.32% | -105.24% | -64.69% | -142.45% | -62.93% | -40.10% | -92.31% | -479.66% | -1,601.33% | -445.38% | -119.61% | -39.21% | -46.30% | 17.47% | -126.58% | -99.37% | -360.47% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -4.64M | -2.78M | 3.04M | -4.61M | -252.00K | 1.33M | -89.00K | -2.17M | 2.04M | 1.71M | -554.00K | 1.28M | -762.00K | 258.00K | -36.00K | 397.00K | 488.00K | 240.00K | 106.00K | 0.00 | -24.00K |
| Income Before Tax | -9.64M | -10.61M | -5.82M | -11.03M | -9.65M | -6.54M | -7.40M | -13.15M | -18.97M | -15.19M | -16.04M | -7.03M | -5.08M | -4.26M | 2.70M | -8.11M | -5.39M | -5.29M | -3.46M | 0.00 | -977.00K |
| Income Before Tax Ratio | -65.46% | -73.65% | -69.16% | -111.07% | -146.26% | -52.29% | -40.59% | -110.52% | -433.03% | -1,441.37% | -461.32% | -101.12% | -46.13% | -43.65% | 17.24% | -120.68% | -91.12% | -344.81% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -3.81M | -4.62M | 5.00K | 6.00K | 4.00K | 3.00K | 2.00K | 12.00K | 2.00K | 2.00K | 2.00K | 2.00K | 50.00K | 7.00K | 2.00K | 12.00K | -240.00K | -106.00K | 2.80M | 0.00 |
| Net Income | -9.64M | -16.27M | -6.56M | -11.04M | -10.49M | -6.55M | -7.40M | -13.15M | -18.97M | -15.19M | -16.04M | -7.03M | -5.09M | -4.31M | 2.70M | -8.11M | -5.40M | -5.29M | -3.46M | -2.80M | -977.00K |
| Net Income Ratio | -65.46% | -112.92% | -77.89% | -111.12% | -158.92% | -52.33% | -40.61% | -110.54% | -433.07% | -1,441.56% | -461.37% | -101.15% | -46.15% | -44.17% | 17.20% | -120.71% | -91.32% | -344.81% | 0.00% | 0.00% | 0.00% |
| EPS | -138.65 | -353.59 | -184.09 | -385.53 | -593.63 | -473.83 | -591.81 | 0.00 | 0.00 | 0.00 | 0.00 | -208.80 | -172.64 | -161.60 | 105.00 | -333.14 | -526.52 | -809.37 | -624.53 | -560.46 | -211.43 |
| EPS Diluted | -138.65 | -353.59 | -184.09 | -385.53 | -593.63 | -564.17 | -591.81 | 0.00 | 0.00 | 0.00 | 0.00 | -210.00 | -172.64 | -161.60 | 105.00 | -333.14 | -526.52 | -809.37 | -624.53 | -560.46 | -211.43 |
| Weighted Avg Shares Out | 120.43K | 30.00K | 31.64K | 28.63K | 16.27K | 11.60K | 12.51K | 0.00 | 0.00 | 0.00 | 0.00 | 33.46K | 29.45K | 26.66K | 25.60K | 24.36K | 10.26K | 6.53K | 5.55K | 5.00K | 4.62K |
| Weighted Avg Shares Out (Dil) | 120.43K | 46.00K | 35.63K | 28.63K | 17.67K | 13.93K | 12.51K | 0.00 | 0.00 | 0.00 | 0.00 | 33.66K | 29.45K | 26.66K | 26.42K | 24.36K | 10.26K | 6.53K | 5.55K | 5.00K | 4.62K |
NovaBay Pharmaceuticals to Reconvene Special Meeting of Stockholders on December 18, 2024
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) (“NovaBay” or the “Company”) announces that its Special Meeting of Stockholders held on November 22, 2024 has been adjourned until December 18, 2024 at 11:00 a.m. Pacific time to provide stockholders additional...
Prominent Independent Proxy Advisory Firm ISS Supports NovaBay Pharmaceuticals' Proposals to Authorize the Sale of its Avenova Brand
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) (“NovaBay” or the “Company”) announces that the largest institutional advisory firm, Institutional Shareholder Services (ISS), has recommended that NovaBay stockholders vote in favor of all of the Company's proxy proposals, specifically to...
NBY Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of NovaBay Pharmaceuticals, Inc.'s Avenova Brand and Business Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of NovaBay Pharmaceuticals, Inc.'s (NYSE American: NBY) Avenova brand and business to Physician Recommended Nutriceuticals, LLC for $9.5 million in cash is fair to NovaBay...
Acumen Health Holdings ("Acumen") to Acquire the Avenova brand from NovaBay Pharmaceuticals
This Acquisition Enhances PRN Physician Recommended Nutriceuticals' ("PRN") Product Portfolio of Science-Based Eye Health Products BLUE BELL, Pa. , Sept. 20, 2024 /PRNewswire/ -- Acumen Health Holdings, LLC, a professionally recommended, consumer-preferred dietary supplements company focused on eye health and companion...
NovaBay Pharmaceuticals Signs Definitive Agreement to Sell its Avenova Assets
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) (“NovaBay” or the “Company”) announces it has entered into a definitive asset purchase agreement (the “Agreement”) with PRN Physician Recommended Nutriceuticals, LLC (“PRN”) to sell the assets of its Avenova® brand and...
NovaBay Pharmaceuticals, Inc. (NBY) Q2 2024 Earnings Call Transcript
NovaBay Pharmaceuticals, Inc. (NYSE:NBY ) Q2 2024 Earnings Conference Call August 13, 2024 4:30 PM ET Company Participants Jody Cain - LHA, Investor Relations Justin Hall - Chief Executive Officer and General Counsel Tommy Law - Interim Chief Financial Officer...
NovaBay Pharmaceuticals Reports Second Quarter 2024 Financial Results
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and six months ended June 30, 2024 and provides a business update. “Revenue growth was driven by higher Avenova sales through online channels including an expanded...
NovaBay Pharmaceuticals Offers 20% Discounts on Avenova Eyecare Products During Amazon Prime Day
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces 20% discounts on Avenova®-branded eyecare products and product bundles during Amazon Prime Day being held July 16-17, 2024. “Prime Day has been a highly productive event for NovaBay in past years...
NovaBay Pharmaceuticals Reports Preliminary Second Quarter 2024 Net Revenue of $2.4 Million
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) (the “Company” or “NovaBay”) announces preliminary net revenue for the second quarter of 2024 of $2.4 million and for the first half of 2024 of $5.0 million, primarily derived from the Company's...
NovaBay Pharmaceuticals Supports National Dry Eye Awareness Month with Multiple Avenova Product Promotions
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces it will be offering special promotions and discounts on its Avenova®-branded eyecare products to customers and eyecare professionals throughout July in support of National Dry Eye Awareness Month. National Dry Eye...
Source: https://incomestatements.info
Category: Stock Reports